Early Stage Investment Forum 

 

Thursday 1 November


A key element of the AusBiotech 2018 conference is a one-day Early Stage Investment Forum featuring 24 presentations
from local research institutes, universities, hospitals and pre-series A companies in the area of human therapeutics and
enabling technologies. The pitches will be made to an expert investor panel that will include international big pharma
representatives as well as corporate VCs and early stage investors.

The forum will be open to AusBiotech attendees and will take place on Thursday 1 November at the AusBiotech 2018 national conference in Brisbane between 9.45am – 5.00pm.

 

Sessions 

   COMPANY/PRESENTER  TITLE
9.45-10.30am Session 1: New therapeutics  
     
  Walter and Eliza Hall Institute (WEHI) Precision epigenetics: silencing SMCHD1 to treat Prader-Willi Syndrome (PWS)
  Institute for Glycomics, Griffith University Novel Therapeutics for Parainfluenza
  UniQuest, The University of Queensland Cell therapy for the treatment of peripheral artery disease
   
   
11.00am-12.30pm Session 2: CNS, Pain & Vaccine  
     
  QEDDI, UniQuest Small molecule therapeutics targeting neuroinflammation in Alzheimer’s disease
  UniQuest, The University of Queensland A novel approach for the treatment of painful diabetic neuropathy
  Vast Bioscience Pty Ltd Novel ion channel blockers for the treatment of pain
  University of Adelaide DNA Vaccine for Hepatitis C and HIV
  UniQuest, The University of Queensland Novel Constructs for flavivirus vaccines
  UniQuest, The University of Queensland Molecular Clamp vaccine platform for RSV and influenza
  James Cook University The development of a hyperstable influenza vaccine
   
   
1.30-3.00pm  Session 3: Oncology   
     
  Hirotsu Bio Australia N-NOSE: a new cancer screening innovation
  QIMR Berghofer MRI Bi-specific antibodies for cancer immunotherapy
  QIMR Berghofer MRI G9a inhibitors for the treatment of breast cancer
  UniQuest, The University of Queensland Adjuvant therapy for improved cancer treatment
  James Cook University Immune Checkpoint inhibitors
  QEDDI, UniQuest First in class ion channel inhibitors for the treatment of cancer
  Edith Cowan University MelDX, a novel IVD test for detection of early stage melanoma
   
   
3.30-5.00pm Session 4: Inflammation and immunology  
     
  UniQuest, The University of Queensland Novel complement modulators for the treament of inflammatory and metabolic diseases
  UniQuest, The University of Queensland IL-22 conjugates for the treatment of NASH
  Walter and Eliza Hall Institute (WEHI) Rethinking CD52: a therapy for autoimmune disease
  Walter and Eliza Hall Institute (WEHI) Intercepting inflammation with RIPK2 inhibitors
  Biomedicine Discovery Institute, Monash University Reset and Maintenance, a novel approach to the treatment of autoimmune diseases
  UniQuest, The University of Queensland HPGD2S inhibitors for asthma and allergic disease

 

Further details on presentation titles, speakers and organisations coming soon.

Contact: For further information, please contact events@ausbiotech.org or +613 9828 1400.